Avery Therapeutics Raises $8.5M Series A Backed by Bija Ventures | VeilStrat

Avery Therapeutics Closes $8.5M Series A

Avery Therapeutics, a Tucson, Arizona biotechnology company, has raised $8.5 million in Series A funding. Bija Ventures participated in the round.

What Avery Therapeutics Does

Avery Therapeutics is spun out of the University of Arizona (Sarver Heart Center). The company develops immunomodulatory biologic therapeutics designed to redirect the immune system toward repair in diseases of aging, inflammation, and fibrosis.

Its lead product, MyCardia, is a tissue-engineered heart graft in pre-clinical development. MyCardia is intended to restore cardiac function in patients with chronic heart failure.

Deal Details

Round type: Series A
Amount: $8,500,000 USD
Investors: Bija Ventures
Funding date: September 21, 2026

Strategic Context

The Series A funding supports Avery Therapeutics as it advances MyCardia, its tissue-engineered heart graft, through pre-clinical development. The company's approach targets chronic heart failure, a condition with significant unmet need, using an immunomodulatory biologic strategy aimed at redirecting the immune system toward repair rather than scarring or inflammation.

Avery's platform is positioned at the intersection of regenerative medicine and immunology, with an initial focus on cardiac repair. The company's academic origins at the University of Arizona's Sarver Heart Center provide a research foundation for its biologic therapeutic programs.

Acquisition Angle

For acquirers in biotech and regenerative medicine, Avery Therapeutics offers a pre-clinical asset in cardiac repair with a differentiated immunomodulatory mechanism. The company's lead program, MyCardia, targets chronic heart failure, a large indication. Strategic buyers may view the platform as an opportunity to add tissue-engineered graft technology and immunomodulatory biologics to their pipelines.

Key Facts

Company: Avery Therapeutics
Headquarters: Tucson, Arizona
Origin: Spun out of the University of Arizona (Sarver Heart Center)
Focus: Immunomodulatory biologic therapeutics for diseases of aging, inflammation, and fibrosis
Lead product: MyCardia, a tissue-engineered heart graft in pre-clinical development for chronic heart failure
Funding stage: Series A
Latest round: $8.5M Series A, with participation from Bija Ventures
Date: September 21, 2026